Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Average Target Price of GBX 2,085.83

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 2,085.83.

HIK has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Citigroup upped their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research report on Friday, September 25th. Finally, Berenberg Bank lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a report on Tuesday, August 11th.

Insider Buying and Selling

In related news, insider Tobias Hestler bought 7,500 shares of the company’s stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is currently owned by insiders.

Hikma Pharmaceuticals Trading Up 0.3%

LON HIK opened at GBX 1,729 on Friday. The stock has a market cap of £3.58 billion, a P/E ratio of 9.82, a PEG ratio of 2.38 and a beta of 0.65. The company’s fifty day simple moving average is GBX 1,619.65 and its 200-day simple moving average is GBX 1,504.79. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 1,865.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.